Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSIS NEWS IN BRIEF
February 12, 2001
- Aiming to Rank 20th within This Year: Mr Payne of Pharmacia
February 12, 2001
- Takeda to Carry Out Reform with Global Standard: President Takeda
February 5, 2001
- 50% of Outpatients Should Pay Fixed Rate Copayment Overall: HIB
February 5, 2001
- WORLD NEWS IN BRIEF
February 5, 2001
- Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -2-
February 5, 2001
- JPA Holds National Convention to Prevent Dispensing Errors
February 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
February 5, 2001
- BUSINESS NEWS IN BRIEF
February 5, 2001
- Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
- Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
- ON THE MOVE
February 5, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
February 5, 2001
- Kirin Obtains Rights to Cerus's Allogeneic Cellular Immune Therapy Technology
February 5, 2001
- NHI Prices of 12 New Ingredients Including Tamiflu, Relenza Approved
February 5, 2001
- Kissei, Teikoku Hormone to Codevelop Threatened Premature Delivery Treatment
February 5, 2001
- Peak Sales of 5 New Drugs Expected to Exceed \10 Bil.: Chuikyo
February 5, 2001
- Proposed Human Genome Research GL Explained by Kyoto Univ. Professor
February 5, 2001
- Chuikyo Members Point Out Problems with NHI Price Setting Rules
February 5, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…